Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolution of Th17 immune response in rheumatoid arthritis patients treated with tocilizumab after failure of other therapies
2010-018696-21Phase 4Active
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoints: Serum IL-17 levels and Serum IL-22 levels. Started Feb 2010; status: active.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-018696-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018696-21.